EUVIMEDEUVIMED entdecken
Crossref

When it comes to therapeutics, new is good, but what we really need are breakthrough drugs and products

Andrew W. Roberts

Blood · 19.11.2026 · 148 (21) · 2553-2555

DOI: 10.1182/blood.2026035564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 19.11.2026. Verfasst von Andrew W. Roberts. Die Arbeit nennt 22 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rather than incremental improvements over existing therapies, the greatest need in hematology is for breakthrough therapeutic agents that address major unmet clinical needs and transform treatment paradigms. In this editorial, Blood Editor-in-Chief Andrew W. Roberts calls for hematologists to prioritize the development and rigorous evaluation of innovative therapies, including optimizing their dose, duration, safety, and applications, while redirecting resources from less impactful drug development toward evidence-based advances that meaningfully improve patient outcomes.

Zitieren

APA

Roberts, A. W. (2026). When it comes to therapeutics, new is good, but what we really need are breakthrough drugs and products. Blood, 148(21), 2553-2555. https://doi.org/10.1182/blood.2026035564

Vancouver

Roberts AW. When it comes to therapeutics, new is good, but what we really need are breakthrough drugs and products. Blood. 2026;148(21):2553-2555. doi:10.1182/blood.2026035564

BibTeX
@article{Roberts2026,
  author = {Roberts, Andrew W.},
  title = {When it comes to therapeutics, new is good, but what we really need are breakthrough drugs and products},
  journal = {Blood},
  year = {2026},
  volume = {148},
  number = {21},
  pages = {2553--2555},
  doi = {10.1182/blood.2026035564}
}
Kostenlos starten →